EHA-SWG Scientific Meeting

 

NEW MOLECULAR INSIGHTS IN EMERGING THERAPEUTIC STRATEGIES IN ACUTE LYMPHOBLASTIC LEUKEMIA

New molecular insights in emerging therapeutic strategies in Acute Lymphoblastic Leukemia
DATES: 28 February-2 March 2014
LOCATION: Lisbon (tbc)
CHAIR: Dr. Dieter Hoelzer
CO-CHAIRS: Nicola Gökbuget, Renato Bassan, Adele Fielding, Robin Foà, Hervé Dombret, Josep RiberaNEW MOLECULAR INSIGHTS IN EMERGING THERAPEUTIC STRATEGIES IN ACUTE LYMPHOBLASTIC LEUKEMIA

DATES: February 28 - March 2, 2014

LOCATION: Lisbon – Portugal

CHAIR: Dieter Hoelzer
CO-CHAIRS: Nicola Gökbuget, Renato Bassan, Adele Fielding, Robin Foà, Hervé Dombret, Josep Ribera

The EHA Scientific Working Group for Adult ALL (EWALL) and EHA organized a three-day meeting focused on recent advances in emerging therapeutic strategies in acute lymphoblastic leukemia.

This meeting covered the individualized treatment strategies in ALL, combination of different treatment modalities; chemotherapy, antibody therapy, targeted inhibitors, stem cell transplantation and new approaches in non-chemo therapy in elderly. In particular, this meeting provided an innovative format that included e.g. Round table discussions. Besides that voting boxes will be used for the self-assessment of participants.

The meeting was targeted towards specialists in hematology, clinicians involved in ALL, basic researchers, biologists, students and everybody interested in this specific section of hematology.

Participants of this meeting were eligible to receive one Continuing Medical Education (CME) credit point for every hour of accredited activity from the EHA-CME system.

A report of this meeting has been published and is now available here.

PROGRAM

Friday, February 28

Time Topic Speaker
13:00-14:00Registration
14:00-14:10Welcome
14:10-15:50SESSION 1: GENETIC ALTERATIONS / MOLECULAR MARKERSCHAIRS: R. FOÀ, J. VAN DONGEN
14:10-14:35Molecular genetics of B-precursor ALLE. Clappier (Paris)
14:35-15:00BCR-ABL-like ALL M. den Boer (Rotterdam)
15:00-15:25Molecular genetics of T-lineage ALLC. Baldus (Berlin)
15:25-15:50Joint discussion
15:50-16:20Coffee break
16:20-18:45SESSION 2: MINIMAL RESIDUAL DISEASE/ METHODS AND APPLICATIONCHAIRS: D. HOELZER, A. ORFAO
16:20-16:45MRD detection by PCRM. Brüggemann (Kiel)
16:45-17:10Novel EuroFlow strategies for flow cytometric MRD detectionJ. van Dongen (Rotterdam)
17:10-17:35Prognostic impact of MRD in adult ALLR. Bassan (Venice)
17:35-18:00Prognostic impact of MRD in pediatric ALLA. Biondi (Milano)
18:00-18:45Interactive case discussion. Panel discussion: Promises and pitfalls in MRD evaluation
18:45-19:45Welcome Reception


Saturday, March 1

Time Topic Speaker
09:00-10:05SESSION 3: DIAGNOSTICSCHAIRS: H. DOMBRET, T. HAFERLACH
09:00-09:25Comprehensive diagnostics in ALL. What is needed? desirable? for research? R. Foà (Rome)
09:25-09:40Interactive case discussion
09:40-10:05A new approach for assessment of occult disease in the CSF A. Orfao (Salamanca)
10:05-10:55SESSION 4: TARGETED THERAPIES IN PH/BCR-ABL POS. ALLCHAIRS: CONT.
10:05-10:30Next generation sequencing for BCR-ABL1 mutation detection in Ph+ leukemiasS. Soverini (Bologna)
10:30-10:55Targeting resistance to TKIsO. Ottmann (Frankfurt)
10:55-11:25Coffee break
11:25-13:05SESSION 5: RESISTANCE AND NOVEL COMPOUNDS AND TARGETED THERAPY WITH MONOCLONAL ANTIBODIES AND LEUKEMIA-SPECIFIC CELL THERAPYCHAIRS: N. GÖKBUGET, S. GIEBEL
11:25-11:50Novel compoundsS. O’Brien (Houston)
11:50-12:15Anti-CD20D. Hoelzer (Frankfurt)
12:15-12:40Anti-CD19M. Topp (Würzburg)
12:40-13:05Anti-CD22S. O’Brien (Houston)
13:05-13:30CART cells in ALLR. Brentjens (New York)
13:30-14:45Lunch
14:45-16:00SESSION 6: CURRENT TREATMENT STRATEGIES AND RESULTSCHAIRS: R. BASSAN, S. O’BRIEN
14:45-16:10Risk stratification in T-lineage ALLH. Dombret (Paris)
15:10-15:35Risk stratification in B-lineage ALLJ. Ribera (Barcelona)
15:35-16:00Elderly ALL – challenging concepts; from palliative care to cureN. Gökbuget (Frankfurt)
16:00-16:30Coffee break
16:30-18:45SESSION 7: STEM CELL TRANSPLANTATIONCHAIRS: J. RIBERA, O. OTTMANN
16:30-16:55SCT in CR1 – indicationsJ. Cornelissen (Rotterdam)
16:55-17:20Autologous SCT - Recent update of EBMT results S. Giebel (Gliwice)
17:20-17:45Haplo-identical SCT F. Ciceri (Milan)
17:45-18:45Round table discussion; EWALL Study groups: Experience with Regulation rules and drug reimbursement for joint ALL studies

Sunday, March 2

Time Topic Speaker
09:00-12:50SESSION 8: TREATMENT APPROACHES FOR ADOLESCENTS AND YOUNG ADULTS (AYAS) CHAIRS: A. BIONDI, D. HOELZER
09:00-09:25What are the genomic differences between children and adults with ALL?T. Haferlach (München)
09:25-09:40Interactive case discussion
Experience of EWALL Study groups
09:40-10:00FranceN. Boissel (Paris)
10:00-10:20Great BritainC. Rowntree (Cardiff)
10:20-10:40ItalyA. M. Testi (Rome)
10:40-11:00Coffee break
11:00-11:20SpainJ. Ribera (Barcelona)
11:20-11:40PolandS. Giebel (Gliwice)
11:40-12:00SwedenH. Hallböök (Uppsala)
12:00-12:20GermanyN. Gökbuget (Frankfurt)
12:20-12:50Panel discussion: Pediatric trials for younger adults: yes or no?
12:50-13:00Conference closure
13:00-14:00Lunch